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Aims Use of inotropic agents in patients with heart failure (HF) has been limited by adverse effects on outcomes. However,
administration of positive inotropes at lower doses and concomitant treatment with beta-blockers might increase
beneﬁt–risk ratio. We investigated the effects of low doses of the positive inotrope enoximone on symptoms, exer-
cise capacity, and major clinical outcomes in patients with advanced HF who were also treated with beta-blockers and
other guideline-recommended background therapy.
Methods
and results
TheStudiesofOralEnoximoneTherapyinAdvancedHF(ESSENTIAL)programmeconsistedoftwoidentical,random-
ized, double-blind, placebo-controlled trials that differed only by geographic location (North and South America:
ESSENTIAL-I; Europe: ESSENTIAL-II). Patients with New York Heart Association class III–IV HF symptoms, left ven-
tricular ejection fraction  30%, and one hospitalization or two ambulatory visits for worsening HF in the previous
year were eligible for participation in the trials. The trials had three co-primary endpoints: (i) the composite of time
to all-cause mortality or cardiovascular hospitalization, analysed in the two ESSENTIAL trials combined; (ii) the
6 month change from baseline in the 6 min walk test distance (6MWTD); and (iii) the Patient Global Assessment
(PGA) at 6 months, both analysed in each trial separately. ESSENTIAL-I and -II randomized 1854 subjects at
211 sites in 16 countries. In the combined trials, all-cause mortality and the composite, ﬁrst co-primary endpoint did
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not differ between the two treatment groups [hazard ratio (HR) 0.97; 95% conﬁdence interval (CI) 0.80–1.17; and HR
0.98; 95% CI 0.86–1.12, respectively, for enoximone vs. placebo]. The two other co-primary endpoints were analysed
separately in the two ESSENTIAL trials, as prospectively designed in the protocol. The 6MWTD increased with enox-
imone, compared with placebo, in ESSENTIAL-I (P ¼ 0.025, not reaching, however, the pre-speciﬁed criterion for stat-
istical signiﬁcance of P , 0.020), but not in ESSENTIAL-II. No difference in PGA was observed in either trial.
Conclusion Although low-dose enoximone appears to be safe in patients with advanced HF, major clinical outcomes are not
improved.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Current treatment of heart failure (HF) with the administration of
neurohormonal antagonists and the use of implantable cardiover-
ter–deﬁbrillators (ICDs) and/or cardiac resynchronization devices
has increased patient survival.
1,2 The administration of neurohor-
monal antagonists may delay, but usually does not halt, the pro-
gression of HF.
3,4 ICDs prevent sudden cardiac death, an event
often occurring at the early stages of the disease, but do not
change, or may even increase,
5 the proportion of patients who
develop worsening HF. Many patients therefore progress to a
stage of advanced chronic HF (ACHF), characterized by high mor-
tality, frequent hospitalizations, marked limitation of exercise
capacity, poor quality of life, and haemodynamic impairment.
6
Impaired left ventricular (LV) pump function likely plays a pivotal
role in ACHF, as shown by the independent prognostic value of
haemodynamicvariables,byintolerancetoneurohormonalantagon-
ists for haemodynamic reasons and by poor exercise capacity.
6–11
These data support the potential usefulness of agents having
direct positive inotropic and lusitropic effects to improve clinical
outcomes, symptoms, and exercise capacity of ACHF
patients.
7,12,13 Enoximone is a non-glycoside, non-catecholamine,
imidazolone derivative that selectively inhibits
sarcoplasmic-reticulum-associated type IIIa and IIIb phosphodi-
esterase, leading to increased levels of intracellular cAMP.
14
Similar to other type III phosphodiesterase inhibitors
(PDEIs),
15,16 long-term administration of enoximone at high
doses ( 100 mg t.i.d.) has been associated with increased mor-
tality in placebo-controlled trials.
14,17,18 These trials were,
however, performed before the introduction of beta-blockers in
the treatment of HF. Beta-blockers can counteract untoward
effects of PDEIs (tachyarrhythmias, tachycardia, excessive increase
in myocardial work, and oxygen consumption) but maintain or
even enhance, through improved intracellular calcium homeostasis,
their beneﬁcial inotropic and lusitropic effects.
12,19–22 Both the
adverse effects and the increased mortality observed with enoxi-
mone administration are dose dependent, and were absent in
trials in which enoximone was administered at doses ,100 mg
t.i.d.
14 These lower doses are associated with an improvement in
haemodynamic parameters and increased exercise tolerance, as
shown by placebo-controlled trials.
14,23,24
We hypothesized that the administration of low doses of enox-
imone in conjunction with optimal neurohormonal blockade could
have a favourable impact on outcome, symptoms, and exercise
capacity in patients with ACHF. To test this hypothesis, the
Studies of Oral Enoximone Therapy in Advanced Heart Failure
(ESSENTIAL) were designed and conducted.
Methods
ESSENTIAL encompassed two trials, with identical protocols differing
only by geographical location: ESSENTIAL-I was conducted in North
and South America, and ESSENTIAL-II in Europe. ESSENTIAL-I and
ESSENTIAL-II were multicentre, randomized, double-blind, placebo-
controlled, parallel group trials. The target enrolment was 900 patients
in each trial, designed to deliver at least 825 ﬁrst co-primary endpoints
and 350 deaths in the two trials combined.
Patients
Inclusion criteria were: age .18 years; HF caused by ischaemic or non-
ischaemic cardiomyopathy; LV systolic dysfunction shown by an ejec-
tion fraction (EF)  30%, detected on radionuclide ventriculography,
two-dimensional echocardiography, or nuclear magnetic resonance
imaging; an echocardiographically determined LV end-diastolic diam-
eter .3.2 cm/m
2 or  6.0 cm; symptoms of dyspnoea or fatigue at
rest or at minimal exertion [New York Heart Association (NYHA)
class III–IV] for .2 months; at least one hospitalization or two outpa-
tient visits requiring intravenous diuretic or vasodilator therapy within
12 months before screening; and optimal medical therapy including
diuretics, beta-blockers, and angiotensin-converting enzyme
(ACE)-inhibitors or angiotensin receptor blockers (ARBs) unless intol-
erant or contraindicated. Exclusion criteria were an acute myocardial
infarction in the previous 90 days, cardiovascular surgery in the pre-
vious 60 days, symptomatic ventricular arrhythmias or ICD ﬁring in
the previous 90 days, serum potassium ,4.0 or .5.5 mEq/L,
digoxin levels .1.2 ng/mL, magnesium levels ,1.0 mEq/L, serum crea-
tinine  2.0 mg/dL, and serum bilirubin .3.0 mg/dL.
The study conformed to the Good Clinical Practice guidelines and
followed the recommendations of the Declaration of Helsinki. The
protocol was approved by each participating centre’s Ethics Review
Board. Written informed consent was obtained from all patients
before enrolment.
Procedures and design
Randomization was preceded by a screening visit occurring 2 to 10
days before entry. Screening included a clinical visit, blood sample
analysis for laboratory examinations (see inclusion and exclusion cri-
teria), a 6 min walk test, and a Patient Global Assessment (PGA) ques-
tionnaire. Patients were randomized 1:1 to enoximone or placebo
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Patients were re-evaluated at 1 and 2 weeks after randomization.
During this second visit, the study drug dose was up-titrated to
50 mg three times daily in patients weighing .50 kg without renal
and hepatic dysfunction who had tolerated the lower dose. All patients
then underwent follow-up clinical visits at 1, 2, 4, 6, 8, 9, 12 months
after randomization and, in the following years, every 4 months until
study termination. Each visit included clinical examination and blood
sampling for analysis of serum bilirubin, creatinine, and potassium.
The study was designed to be terminated with study drug discon-
tinuation after accumulation of a pre-speciﬁed number of events
(n ¼ 956).
15 After the end of the study, subjects had to be carefully
observed for the ﬁrst 30 days with clinical visits after 7 and 30 days.
Blinded study medication could be re-initiated if a subject showed
rapid deterioration caused by worsening HF that was documented in
a dedicated case report form.
In order to assess the effects of treatment on exercise capacity and
symptoms, the 6 min walk test distance (6MWTD) was measured at
the screening visit, at randomization, and at 6 and 12 months after
study entry, and PGA was measured at 6 and 12 months after study
entry. For 6MWTD, the results obtained at randomization were
used as baseline, and the test was performed according to the standard
protocol.
25 Patient Global Assessment was performed by asking the
patients to rank their change in symptoms compared with baseline
prior to randomization using a seven-level scale that included cat-
egories of marked, moderate, and slight improvement; no change;
and slight, moderate, and marked worsening, compared with how
they felt prior to the start of treatment.
ESSENTIAL-I and ESSENTIAL-II were multicentre, randomized,
double-blind, placebo-controlled, parallel group trials. The investi-
gators and all the centre staff members, the personnel at the sponsor-
ing company, including the Medical Monitor, the personnel at the
CROs, as well as the Members of the Morbidity and Mortality Com-
mittee and the Members of the Steering Committee, were all
blinded to treatment assignment. If safety concerns emerged during
the trial, where the knowledge of the treatment received could have
inﬂuenced future treatment decisions, investigators could be unblinded
on a case-by-case basis. Only in the case of an emergency was the
investigator allowed to proceed with unblinding without ﬁrst contact-
ing the sponsoring company Medical Monitor. An unblinded DSMB
monitored the progress of the trial. Five pre-deﬁned interim analyses
were planned testing for efﬁcacy. The ﬁrst primary endpoint (time
to death or cardiovascular hospitalization) and mortality alone, but
not the other two primary endpoints (6MWTD changes from baseline
to 6 months and PGA at 6 months), were monitored for the possible
early termination of the trial for beneﬁt. The trial could not be stopped
for efﬁcacy unless the 95% conﬁdence interval (CI) for the mortality
difference, based on pooled data for the two ESSENTIAL trials,
excluded a hazard ratio (HR) (enoximone/placebo) .1.30.
Endpoints
ESSENTIAL had three co-primary endpoints for efﬁcacy, plus one
major safety endpoint. Efﬁcacy endpoints encompassing major clinical
outcomes, submaximal exercise capacity, and symptoms were assessed
using the following variables: (i) time from randomization to the com-
posite endpoint of all-cause mortality or cardiovascular hospitalization;
(ii) change from baseline to 6 months in the 6MWTD; (iii) PGA at
6 months. Hospitalization was deﬁned as a non-elective hospital admis-
sion of .24 h duration or including at least one overnight stay docu-
mented by a calendar date change. Cardiovascular hospitalization was
deﬁned as an admission for worsening HF, myocardial infarction,
stroke, atrial or ventricular arrhythmias, or symptomatic heart block.
All potential events were reviewed and classiﬁed by an Endpoints
Committee blinded to treatment assignment. All-cause mortality was
the major safety endpoint. The goal of the mortality analysis was to
demonstrate non-inferiority of enoximone compared with placebo,
deﬁned as the all-cause mortality HR upper bound 95% CI being
,1.30.
Statistical analysis
ESSENTIAL used a novel hybrid statistical design in which the two
ESSENTIAL trials were combined for the analysis of the ﬁrst
co-primary endpoint (time to all-cause mortality or cardiovascular
hospitalizations) and for safety (all-cause mortality), but were analysed
separately for the two other co-primary endpoints (6MWTD and
PGA). Efﬁcacy was considered demonstrated if either the analysis of
the ﬁrst co-primary endpoint (time to all-cause mortality or cardiovas-
cular hospitalization) indicated beneﬁt at a two-sided P-value ,0.007,
or if one of the two other co-primary endpoints (6MWTD and PGA)
indicated beneﬁt at a two-sided P ,0.02 in both ESSENTIAL-I and
ESSENTIAL-II. The different levels of statistical signiﬁcance were
based on negotiations with Food and Drug Administration (FDA)
and were derivative of the goal of proving that low-dose enoximone
added to optimal medical treatment, including beta-blockade, was
safe and efﬁcacious for improving clinical outcomes, exercise capacity,
and symptoms.
14 A major clinical outcome accepted by FDA in HF
indications is the composite of all-cause mortality and cardiovascular
hospitalization. ESSENTIAL was planned as an event-driven trial
based on this major clinical endpoint. During the planning phase of
the ESSENTIAL trials, FDA’s CardioRenal Division informed the
sponsor that their regulatory criterion for proof of efﬁcacy in a
single trial with a time to event major clinical endpoint is a P-value
of ,0.007. In order to be able to detect the desired 26% reduction
in this endpoint at this critical value, 825 primary events were necess-
ary to achieve 90% power, and 956 primary events were required to
achieve 94% power.
14 FDA required that the two other primary end-
points, based on less objective data, achieve signiﬁcance in two separ-
ate trials. Thus, ESSENTIAL-I and ESSENTIAL-II functioned as a single
trial with respect to the ﬁrst primary endpoint, and as two separate
trials for the second and third co-primary endpoints. Critical values
of 0.02 were assigned to 6MWTD/submaximal exercise and PGA/
symptom assessment, in each ESSENTIAL trial. On the basis of these
critical values, it was calculated that the randomization of 900 patients
in each ESSENTIAL trial would have .90% power to detect a treat-
ment group difference of 23 m in the change from baseline of the
6MWTD, and a 14% absolute difference between groups in the
number of subjects moderately or markedly improved by the PGA.
For safety, it was calculated that the occurrence of 350 deaths
would have a 90% power to rule out a  30% increase (upper two-
sided 95% conﬁdence limit of 1.30) in the risk of death for enoximone
vs. placebo. A conservative stopping rule for excess mortality was
deﬁned by the independent Data and Safety Monitoring Board to
ensure safety throughout the study.
14
All randomized subjects were to be followed to the end of the study
and included in the analyses of efﬁcacy according to their randomized
treatment group, with patients included at the moment they took the
ﬁrst trial tablet (intent-to-treat analysis). The time to an event was cal-
culated using the Kaplan–Meier method, and survival curves were com-
paredusingthe log-rank test,stratiﬁed by trial. The relative riskand 95%
CI were estimated with a Cox’s proportional hazard model, with treat-
ment as the only covariate. The Wilcoxon rank-sum test was used to
compare both the PGA at 6 months and the change from baseline to
6 months in the 6MWTD between treatment groups. Missing values
at 6 months were replaced with the last post-randomization
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measurement existed. Changes in the 6MWTD were also analysed by
ANCOVA using baseline value as a covariate as well as centre as a cov-
ariate, since randomization was stratiﬁed by centre.
Pre-speciﬁed analyses included subgroup analyses for interactions
between baseline variables and outcomes as well as 6MWTD
changes from baseline. As part of pre-speciﬁed model diagnostics,
log cumulative hazard plots were performed to detect changes in
HR of enoximone vs. placebo over time, with respect to the
primary endpoint or total mortality. When a change in HR over
time was detected or suggested, a post hoc analysis was performed
to compare the HRs in the ﬁrst half of the study with the last half,
using the median follow-up time to designate the two groups.
Prior to the initiation of the study, the contract research organiz-
ation conducting the study (Inveresk) prepared the double-blind ran-
domization scheme with participants allocated to either enoximone
or placebo in a 1:1 ratio, blocked by the study centre. Unique
subject numbers were assigned within a centre in the order of ran-
domization (investigators gave the lowest medication kit number
received at their site to their ﬁrst subject, etc.). The random allocation
sequence was concealed to the investigators throughout the study.
Results
Patient population
A total of 1854 patients were enrolled (904 patients in
ESSENTIAL-I and 950 patients in ESSENTIAL-II). Recruitment
took place at 211 sites in 16 countries. The trial began on 1 Feb-
ruary 2002 and recruitment ended on 30 May 2004. Follow-up for
the primary endpoints and safety was concluded on 1 December
2004. Median follow-up duration was of 16.6 months
[inter-quartile range (IQR) 8.9–24.0 months; minimum 0.2
months; maximum 34.1 months].
Of the 1854 patients included, 926 were randomized to enoxi-
mone (454 patients in ESSENTIAL-I and 472 in ESSENTIAL-II) and
928 to placebo (450 in ESSENTIAL-I and 478 in ESSENTIAL-II).
Two patients were lost to follow-up (one on placebo and one
on enoximone). Patients who were prematurely withdrawn from
the study because of death, LV assist device implantation, cardiac
transplantation, or other reasons are shown in Table 1.
Baseline characteristics of the patients enrolled in ESSENTIAL-I,
ESSENTIAL-II, and the two trials combined are shown in Table 2.
Signiﬁcant differences in baseline characteristics were found
between the patients in the two trials. These involved both demo-
graphics and characteristics reﬂecting the severity of HF. The per-
centages of females, non-Caucasian patients, and patients with
ischaemic heart disease were higher in ESSENTIAL-I, compared
with ESSENTIAL-II. Regarding HF severity, the patients enrolled
in ESSENTIAL-I had longer duration of HF, lower LVEF, larger
LV end-diastolic diameter, lower 6MWTD, and systolic blood
pressure (SBP), consistent with more advanced HF population.
Patients in ESSENTIAL-I also had a lower likelihood to be
treated with beta-blockers and renin–angiotensin inhibitors. In
both trials, patients randomized to enoximone or placebo were
similar with respect to all baseline characteristics.
Mortality and mortality or cardiovascular
hospitalizations
As prospectively designed, outcome endpoints (e.g. all-cause mor-
tality, as safety endpoint, and all-cause mortality and cardiovascular
.................................................................. ..................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
Table 1 Patients’ follow-up
ESSENTIAL-I ESSENTIAL-II
Status All (n 5 904),
n (%)
Placebo
(n 5 450), n (%)
Enoximone
(n 5 454), n (%)
All (n 5 950),
n (%)
Placebo
(n 5 478), n (%)
Enoximone
(n 5 472), n (%)
Completed the study alive
a 552 (61) 271 (60) 281 (62) 649 (68) 334 (70) 315 (67)
Withdrew prematurely due to
LVAD, transplant, or death
242 (27) 126 (28) 116 (26) 201 (21) 96 (20) 105 (22)
Death 212 (23) 111 (25) 101 (22) 187 (20) 92 (19) 95 (20)
LVAD placement 4 (0.7) 2 (0.4) 2 (0.4) 3 (0.3) 1 (0.2) 2 (0.4)
Heart transplant 26 (3) 13 (3) 13 (3) 11 (1) 3 (1) 8 (2)
Withdrew prematurely for other
reasons
110 (12) 53 (12) 57 (13) 100 (11) 48 (10) 52 (11)
Consent withdrawn 63 (7) 29 (6) 34 (7) 60 (6) 28 (6) 32 (7)
Non-compliance 11 (1) 6 (1) 5 (1) 8 (1) 4 (1) 4 (1)
Marked deterioration in clinical
status
6 (1) 1 (0.2) 5 (1) 3 (0.3) 2 (0.4) 1 (0.2)
Adverse event 13 (1) 8 (2) 5 (1) 12 (1) 3 (1) 9 (2)
Treatment with excluded drug 2 (0.2) 2 (0.4) 0 0 0 0
Other 15 (2) 7 (2) 8 (2) 17 (2) 11 (2) 6 (1)
Lost to follow-up
b 00 0 21 1
aSummarizes subjects whom investigators indicated as having completed the study at the ‘ofﬁcial end of study’ as per protocol on the TERM CRF.
bThese patients were censored at the time of lost to follow-up and kept in the intention-to-treat analysis.
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Table 2 Patients’ characteristics
Parameter ESSENTIAL-I ESSENTIAL-II P-value
a (ESSENTIAL-I vs. -II)
All (n 5 904) Placebo (n 5 450) Enoximone (n 5 454) All (n 5 950) Placebo (n 5 478) Enoximone (n 5 472)
Age (years) 62+13 62+13 63+13 62+11 62+11 62+11 0.3118
Gender, M/F (%) 74/26 72/28 75/25 86/14 87/13 85/15 ,0.0001
Black/Caucasian/Hispanic/other (%) 11/67/18/2 10/66/20/5 11/68/17/4 0/100/00 0/100/00 0/100/0/0 ,0.0001
NYHA class, II/III/IV (%) 1/91/8 1/91/9 1/91/8 0/91/9 0/92/8 0/90/10 0.0706
Ischaemic/non-ischaemic aetiology (%) 52/48 48/52 55/45 59/41 61/39 58/42 0.0008
Weight, kg 80+21 79+21 80+22 81+14 81+14 80+14 0.0004
Duration of HF, months 69+65 70+66 67+64 55+55 55+57 55+52 ,0.0001
HF hospitalization, last 12 months (%) 90 90 90 87 86 88 0.0179
LV ejection fraction (%) 22.3+5.8 22.6+5.6 22.0+6.0 24.8+4.8 24.9+4.8 24.8+4.7 ,0.0001
LV end-diastolic diameter (cm) 6.98+0.78 6.99+0.76 6.96+0.79 6.92+0.70 6.92+0.71 6.92+0.70 0.3124
6 min walk test distance (m) 274+118 278+118 270+118 293+121 294+121 292+121 0.0096
Systolic blood pressure (mmHg) 110+17 109+16 111+18 122+18 122+19 121+18 ,0.0001
Heart rate (b.p.m.) 74+11 74+11 74+11 75+12 74+13 75+11 0.1344
Concomitant treatment
Beta-blockers [n
b (%)] 754 (83) 376 (84) 378 (83) 857 (90) 433 (91) 424 (90) ,0.0001
Carvedilol 533 (59) 413 (43) ,0.0001
Beta-1 selective 200 (22) 440 (46) ,0.0001
Renin–angiotensin inhibitors 850 (94) 376 (94) 378 (94) 937 (99) 473 (99) 464 (98) ,0.0001
ACE-inhibitors 693 (77) 339 (75) 354 (78) 860 (91) 437 (91) 423 (90) ,0.0001
ARBs 160 (18) 86 (19) 74 (16) 72 (8) 36 (8) 36 (8) ,0.0001
Spironolactone 564 (62) 286 (64) 278 (61) 509 (54) 261 (55) 248 (53) 0.0001
Diuretics 863 (95) 432 (96) 431 (95) 914 (96) 460 (96) 454 (96) 0.4210
Digitalis glycosides 624 (69) 314 (70) 310 (68) 437 (46) 221 (46) 216 (46) ,0.0001
Warfarin 281 (31) 72 (8) ,0.0001
Amiodarone 202 (22) 129 (14) ,0.0001
ICD 189 (21) 101 (22) 88 (19) 47 (5) 24 (5) 23 (5) ,0.0001
Permanent pacemaker 276 (31) 137 (30) 139 (31) 109 (11) 45 (9) 64 (14) ,0.0001
Continuous data expressed as mean values, þ/2 standard deviation.
aSigniﬁcance for ESSENTIAL-I vs. ESSENTIAL-II comparisons. HF, heart failure; LV, left ventricular; ACE, angiotensin-converting enzyme; ARBs, angiotensin receptor
blockers; ICD, implantable cardioverter–deﬁbrillator.
bNumber of patients.
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9hospitalizations, as ﬁrst co-primary endpoint) were analysed with
the two ESSENTIAL trials combined. Kaplan–Meier estimates of
time to all-cause mortality for each treatment (safety endpoint)
are shown in Figure 1. Of the 926 patients, 196 (21.2%) died in
the enoximone group compared with 203 of 928 patients
(21.9%) in the placebo group (HR 0.97; 95% CI 0.80–1.17; P ¼
0.73 for enoximone vs. placebo).
Kaplan–Meier estimates of the time to all-cause mortality or
cardiovascular hospitalization for each treatment in the two
ESSENTIAL trials combined analysis (ﬁrst co-primary endpoint)
are shown in Figure 1. Of the 926 patients, 458 (49.5%) died or
had a cardiovascular hospitalization in the enoximone group com-
pared with 465 of 928 patients (50.1%) in the placebo group (HR
0.98; 95% CI 0.86–1.12; P ¼ 0.71). Similar results were found with
respect to the all-cause mortality or HF hospitalization combined
secondary endpoint (HR 0.97; 95% CI 0.84–1.12; P ¼ 0.68). No
differences between the results of the two ESSENTIAL trials
were found when they were analysed separately with respect to
outcomes.
Exercise capacity and symptoms
As prospectively designed, the other two co-primary endpoints,
changes from baseline in the 6MWTD and the PGA at 6
months, were analysed in the ESSENTIAL-I and ESSENTIAL-II
trials separately. In ESSENTIAL-I, median (IQR) change from base-
line was 10 m (260 to 64 m) with enoximone vs. 0 m (291 to
50 m) with placebo (P ¼ 0.025). This did not attain pre-speciﬁed
criteria for treatment group difference (23 m) and for statistical
signiﬁcance (P , 0.02). In ESSENTIAL-II, 6MWTD increased with
both enoximone and placebo: 16.5 m (223 to 60 m) with enoxi-
mone vs. 15 m (220 to 60 m) with placebo (P ¼ 0.82) (Figure 2).
Using ANCOVA, the resulting P-values for change in 6MWTD
were P ¼ 0.16 for ESSENTIAL-I and P ¼ 0.57 for ESSENTIAL-II.
Similar changes in PGA were observed in the enoximone and
placebo groups in either trial. A moderate or marked improvement
in symptoms was observed in 197/454 patients (43%) on enoxi-
mone compared with 207/450 patients (46%) on placebo in
ESSENTIAL-I (P ¼ 0.79) and in 135/472 patients (29%) on
Figure 1 Kaplan–Meier estimates of the time to the safety endpoint of death (up) and to the primary endpoint of death or cardiovascular
hospitalization (bottom).
Figure 2 Median change from baseline (BSL) in the 6 min walk
distance (6MWD) in the two ESSENTIAL trials.
M. Metra et al. 3020enoximone compared with 150/478 patients (31%) on placebo in
ESSENTIAL-II (P ¼ 0.11).
Haemodynamic parameters
Absolute changes from baseline in heart rate and SBP in
ESSENTIAL-I and ESSSENTIAL-II are shown in Figure 3. Differences
were found between the two trials. Heart rate was unchanged in
patients receiving enoximone, compared with those on placebo,
in ESSENTIAL-I. In contrast, patients receiving enoximone in
ESSENTIAL-II showed a higher heart rate compared with those
on placebo, at most of the follow-up visits.
No signiﬁcant difference between patients randomized to enox-
imone or placebo was found for baseline SBP. However, SBP
tended to increase with enoximone compared with placebo,
after 12 months, in ESSENTIAL-I, while SBP values in the two
treatment groups were virtually superimposable at all time points
in ESSENTIAL-II.
Subgroup analyses
Pre-speciﬁed subgroup analyses are shown in Figures 4–6. There
was a statistically signiﬁcant interaction between baseline LVEF
and 6MWTD changes (Figure 6; P ¼ 0.016), with the greatest treat-
ment effect observed among patients with an LVEF ,25% (median
value). Overall, the 6MWTD increased from baseline by 15 m with
enoximone vs. 0 m with placebo in these patients (P ¼ 0.007).
Similar responses were found when the two trials were considered
separately (change from baseline of 10 m with enoximone vs.
25 m with placebo, P ¼ 0.004 in ESSENTIAL-I, and of 20 m with
enoximone vs. 8 m with placebo, P ¼ 0.51 in ESSENTIAL-II). No
other signiﬁcant interactions in the pre-deﬁned subgroups were
observed (Figure 6).
A post hoc analysis, prompted by inspection of the Kaplan–Meier
curves, showed an interaction between follow-up duration and the
effects of enoximone on death or cardiovascular hospitalization
(P , 0.01). The incidence of death or cardiovascular hospitaliz-
ations was similar between enoximone and placebo during the
ﬁrst 16.4 months (median value) (420/926 patients, 45.4% vs.
409/928 patients, 44.1%, respectively), whereas it tended to be
lower with enoximone during the second half of follow-up (38/
303 patients, 12.5%, on enoximone vs. 56/322 patients, 17.4%,
on placebo; P ¼ 0.09). A trend (P ¼ 0.16) for signiﬁcant interaction
by the length of follow-up was also found for all-cause mortality, as
enoximone reduced mortality in the second half of the trial (24/
447 deaths, 5.4%, on enoximone vs. 41/467 deaths, 8.8%, on
placebo; P ¼ 0.045).
Adverse events
Most frequently reported adverse events are summarized in
Table 3. Enoximone administration was associated with a greater
incidence of diarrhoea and palpitations. No difference was found
with regard to any other adverse events.
Figure 3 Change from baseline in the heart rate and systolic blood pressure in the two ESSENTIAL trials. Data shown are mean+standard
error. *P , 0.05.
Effects of low-dose oral enoximone administration 3021Re-initiation of study drug after
end of study
In the month following termination of the trial and study drug with-
drawal, study drug was blindly re-initiated for clinical reasons in 171
of 418 patients (41%) who were on enoximone compared with
139 of 423 patients who were on placebo (33%, P ¼ 0.018 for
comparison between the two treatment groups). The main cause
of re-initiation of the study drug was worsening HF occurring in
163/418 patients on enoximone (39%) vs. 130/423 patients on
placebo (31%, P ¼ 0.014). This was mainly reported as an increase
in HF symptoms (34% of patients previously on enoximone vs. 26%
of patients on placebo; P ¼ 0.013), whereas the incidence of HF
hospitalizations or emergency visits was similar. Also, the incidence
of other cardiovascular events during the month following trial ter-
mination was similar in the two treatment groups.
Discussion
Effects on outcome
ESSENTIAL is the ﬁrst clinical trial powered to assess an effect on
mortality that has demonstrated that a type III PDEI administered
at haemodynamically active doses has no untoward effects in
patients with HF. Our results differ from those of previous
placebo-controlled trials with PDE-Is.
15–18 This difference may
be explained by many factors including patient selection, exclusion
of patients with low- or high-serum potassium levels or serum
digoxin concentrations .1.2 ng/mL, concomitant beta-blocker
therapy, and/or the administration of low doses of enoximone in
our trial. The results show that oral enoximone may be a safe long-
term treatment for appropriately selected patients with ACHF.
Despite the encouraging safety proﬁle, our results did not reveal
evidence of efﬁcacy on clinical outcomes in the entire ESSENTIAL
cohort. This may be due to either a lack of a favourable effect of
enoximone, insufﬁcient follow-up duration, or the study popu-
lation’s characteristics. It is possible, for example, that the inclusion
of only patients with more severe haemodynamic impairment
would have allowed the detection of a favourable effect on out-
comes (Figures 4 and 5).
Patients’ follow-up in the month following termination of the
trial and study drug withdrawal demonstrated a higher re-initiation
rate of study drug in the enoximone, compared with the placebo,
group. This may be interpreted as evidence of continuous ben-
eﬁcial pharmacological activity of the drug, or as a rebound
effect secondary to cardiac function becoming dependent on
drug effects. Similar results have been found in digoxin withdrawal
studies.
26
Effects on exercise capacity
and symptoms
Enoximone administration was not associated with beneﬁcial
effects on symptoms and/or exercise capacity. These results are
in contrast with the beneﬁcial effects shown in placebo-controlled
trials in which enoximone was administered at doses similar as in
ESSENTIAL.
14,23,24 This relatively unexpected ﬁnding may be
explained by either methodological issues and/or characteristics
Figure 4 Hazard ratios and 95% conﬁdence intervals for all-cause death, according to the baseline characteristics of the patients. P-values are
for interaction.
M. Metra et al. 3022of the patients studied. Exercise capacity was assessed in ESSEN-
TIAL by 6MWTD. This method has the advantages of being easy
to perform, suitable for use in multicentre trials, and similar to
everyday physical activity. However, its reproducibility and accu-
racy in detecting an improvement in exercise performance may
be signiﬁcantly reduced in large multicentre trials.
27,28 It may also
be that enoximone has more favourable effects on maximal,
rather than submaximal, exercise performance.
23,24
Our results were inﬂuenced by the characteristics of the
patients studied. This is shown by the comparison between the
two ESSENTIAL trials. The patients enrolled in ESSENTIAL-I,
who had more advanced HF compared with those in
ESSENTIAL-II, showed an improvement in their 6MWTD with
enoximone, compared with placebo. Second, subgroup analysis
indicated interaction between the changes from baseline in the
6MWTD and LVEF at entry into the study. The study suggests
that enoximone may favourably affect exercise capacity when
administered to patients with severe impairment of LV systolic
function. Patients with less severe impairment of LV function are
more likely to be limited by peripheral, skeletal muscle-dependent,
mechanisms rather than by an abnormal haemodynamic response
to exercise.
Both with respect of outcomes and of 6MWTD changes, our
results did not show a worse response to enoximone adminis-
tration in the patients with more advanced HF (e.g. those with a
lower LVEF, low SBP, NYHA class IV). These results are in con-
trast with those obtained with chronic milrinone treatment,
showing a worse outcome compared with placebo, in patients
with more advanced HF.
15 Drug characteristics, use of lower
dosages, and ongoing beta-blocker treatment may explain these
differences.
................................................................................
Table 3 Adverse events
Event Placebo
(n 5 928), n (%)
Enoximone
(n 5 926), n (%)
P-value
a
Worsening heart
failure
364 (39) 360 (39) 0.8782
Dizziness 102 (11) 115 (12) 0.3390
Hypotension 94 (10) 113 (12) 0.1563
Diarrhoea 62 (7) 110 (12) 0.0001
Chest pain 90 (10) 82 (9) 0.5316
Nausea 64 (7) 77 (8) 0.2412
Palpitations 47 (5) 74 (8) 0.0107
Hyperkalaemia 64 (7) 57 (6) 0.5183
Hypokalaemia 65 (7) 69 (7) 0.7101
Increased serum
creatinine
62 (7) 61 (7) 0.9355
Cough 64 (7) 61 (7) 0.7907
Headache 54 (6) 59 (6) 0.6190
Sudden death
unexplained
54 (6) 57 (6) 0.7601
Atrial ﬁbrillation 48 (5) 43 (5) 0.5982
aDifferences between placebo and enoximone.
Figure 5 Hazard ratios and 95% conﬁdence intervals for the primary endpoint of all-cause death or cardiovascular hospitalization, according
to the baseline characteristics of the patients. P-values are for interaction.
Effects of low-dose oral enoximone administration 3023Conclusions
The ESSENTIAL-I and -II trials indicate that low-dose enoximone
added to contemporary medical therapy is safe, but does not
produce favourable effects on the three primary endpoints as
deﬁned in the statistical analysis plan. Further studies of inotropic
agents in advanced HF may want to take these observations into
consideration.
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